MedTrace Logo

BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy

NCT01806649 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-10-11

No results posted yet for this study

Summary

There is a need for more effective therapy for patients with esophageal squamous cell carcinoma who developed disease progression after first line therapy. Currently, there is no standard second-line therapy for this disease.

BKM-120 is a pan-PI3K inhibitor currently tested in clinical trials. In a cellular model of oral-esophageal carcinogenesis, it has shown that EGFR overexpression activated PI3/AKT pathway. Therfore, there is interest to see the efficacy and safety of BKM120 in this setting.

Conditions

  • Esophageal Cancer

Interventions

DRUG

BKM120

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Arunee Dechaphunkul, MD · Prince of Songkla University, Thailand

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-01
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01806649 on ClinicalTrials.gov